INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES

INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES

An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more -OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: NOH, Sang Myoung, LIM, Jong Lae, JUNG, Sung Bum, KO, Jin Young
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator NOH, Sang Myoung
LIM, Jong Lae
JUNG, Sung Bum
KO, Jin Young
description An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more -OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to be easily applied to pharmaceutical preparations in dosage forms, and forms a liquid crystal in an aqueous fluid phase so that sustained-release effects of GnRH analogue, which is used as a pharmaceutically active substance in vivo, are exhibited. In addition, in an injectable composition of the present invention, a sustained-release lipid initial preparation comprising GnRH analogue includes water, and thus a liquid injectable agent forms a liquid crystal gel immediately after administration, so that the effects of reducing initial release rate and remarkably increasing sustained-release properties of the drug are exhibited.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4173614A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4173614A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4173614A43</originalsourceid><addsrcrecordid>eNrjZDDy9PNydQ5xdPJxVXD29w3wD_YM8fT3A7ODPIM9_dwV3P2CPBRcXIM8wxxDPMNcg3kYWNMSc4pTeaE0N4OCm2uIs4duakF-fGpxQWJyal5qSbxrgImhubGZoYmjiTERSgBWQibQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES</title><source>esp@cenet</source><creator>NOH, Sang Myoung ; LIM, Jong Lae ; JUNG, Sung Bum ; KO, Jin Young</creator><creatorcontrib>NOH, Sang Myoung ; LIM, Jong Lae ; JUNG, Sung Bum ; KO, Jin Young</creatorcontrib><description>An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more -OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to be easily applied to pharmaceutical preparations in dosage forms, and forms a liquid crystal in an aqueous fluid phase so that sustained-release effects of GnRH analogue, which is used as a pharmaceutically active substance in vivo, are exhibited. In addition, in an injectable composition of the present invention, a sustained-release lipid initial preparation comprising GnRH analogue includes water, and thus a liquid injectable agent forms a liquid crystal gel immediately after administration, so that the effects of reducing initial release rate and remarkably increasing sustained-release properties of the drug are exhibited.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240814&amp;DB=EPODOC&amp;CC=EP&amp;NR=4173614A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240814&amp;DB=EPODOC&amp;CC=EP&amp;NR=4173614A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NOH, Sang Myoung</creatorcontrib><creatorcontrib>LIM, Jong Lae</creatorcontrib><creatorcontrib>JUNG, Sung Bum</creatorcontrib><creatorcontrib>KO, Jin Young</creatorcontrib><title>INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES</title><description>An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more -OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to be easily applied to pharmaceutical preparations in dosage forms, and forms a liquid crystal in an aqueous fluid phase so that sustained-release effects of GnRH analogue, which is used as a pharmaceutically active substance in vivo, are exhibited. In addition, in an injectable composition of the present invention, a sustained-release lipid initial preparation comprising GnRH analogue includes water, and thus a liquid injectable agent forms a liquid crystal gel immediately after administration, so that the effects of reducing initial release rate and remarkably increasing sustained-release properties of the drug are exhibited.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDy9PNydQ5xdPJxVXD29w3wD_YM8fT3A7ODPIM9_dwV3P2CPBRcXIM8wxxDPMNcg3kYWNMSc4pTeaE0N4OCm2uIs4duakF-fGpxQWJyal5qSbxrgImhubGZoYmjiTERSgBWQibQ</recordid><startdate>20240814</startdate><enddate>20240814</enddate><creator>NOH, Sang Myoung</creator><creator>LIM, Jong Lae</creator><creator>JUNG, Sung Bum</creator><creator>KO, Jin Young</creator><scope>EVB</scope></search><sort><creationdate>20240814</creationdate><title>INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES</title><author>NOH, Sang Myoung ; LIM, Jong Lae ; JUNG, Sung Bum ; KO, Jin Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4173614A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>NOH, Sang Myoung</creatorcontrib><creatorcontrib>LIM, Jong Lae</creatorcontrib><creatorcontrib>JUNG, Sung Bum</creatorcontrib><creatorcontrib>KO, Jin Young</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NOH, Sang Myoung</au><au>LIM, Jong Lae</au><au>JUNG, Sung Bum</au><au>KO, Jin Young</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES</title><date>2024-08-14</date><risdate>2024</risdate><abstract>An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more -OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to be easily applied to pharmaceutical preparations in dosage forms, and forms a liquid crystal in an aqueous fluid phase so that sustained-release effects of GnRH analogue, which is used as a pharmaceutically active substance in vivo, are exhibited. In addition, in an injectable composition of the present invention, a sustained-release lipid initial preparation comprising GnRH analogue includes water, and thus a liquid injectable agent forms a liquid crystal gel immediately after administration, so that the effects of reducing initial release rate and remarkably increasing sustained-release properties of the drug are exhibited.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP4173614A4
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title INJECTABLE COMPOSITION COMPRISING GNRH DERIVATIVES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T04%3A46%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NOH,%20Sang%20Myoung&rft.date=2024-08-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4173614A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true